OmniAb (NASDAQ:OABI – Get Free Report) and Alpha Teknova (NASDAQ:TKNO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Earnings and Valuation
This table compares OmniAb and Alpha Teknova”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OmniAb | $38.46 million | 17.54 | -$64.78 million | ($0.36) | -12.94 |
| Alpha Teknova | $43.70 million | 7.89 | -$17.26 million | ($0.31) | -20.71 |
Alpha Teknova has higher revenue and earnings than OmniAb. Alpha Teknova is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for OmniAb and Alpha Teknova, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
| Alpha Teknova | 1 | 1 | 4 | 0 | 2.50 |
OmniAb presently has a consensus target price of $11.50, indicating a potential upside of 146.78%. Alpha Teknova has a consensus target price of $8.75, indicating a potential upside of 36.29%. Given OmniAb’s higher possible upside, research analysts clearly believe OmniAb is more favorable than Alpha Teknova.
Risk and Volatility
OmniAb has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500.
Profitability
This table compares OmniAb and Alpha Teknova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OmniAb | -115.12% | -16.59% | -14.82% |
| Alpha Teknova | -38.37% | -24.94% | -16.53% |
Institutional and Insider Ownership
72.1% of OmniAb shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Comparatively, 13.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Alpha Teknova beats OmniAb on 7 of the 13 factors compared between the two stocks.
About OmniAb
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
About Alpha Teknova
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
